The chemokine CCL5 as a potential prognostic factor predicting disease progression in stage II breast cancer patients

Clinical Cancer Research

Volumn 12, Issue 15, 2006, Pages 4474-4480

  Yaal Hahoshen, Neora ^a   Shina, Sima ^a   Leider Trejo, Leonor ^a   Barnea, Itay ^a   Shabtai, Esther L ^a   Azenshtein, Elina ^a   Greenberg, Iulia ^a   Keydar, Iafa ^a   Ben Baruch, Adit ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; PROGESTERONE RECEPTOR; RANTES;

ADULT; AGED; BREAST CANCER; CANCER GROWTH; CANCER STAGING; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; RISK ASSESSMENT; TUMOR CELL;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CHEMOKINE CCL5; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 33748061991     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-0074     Document Type: Review

References (32)

1. Platet N, Cathiard AM, Gleizes M, Garcia M. Estrogens and their receptors in breast cancer progression: a dual role in cancer proliferation and invasion. Crit Rev Oncol Hematol 2004;51:55-67.
2. Hayashi SI, Eguchi H, Tanimoto K, et al. The expression and function of estrogen receptor α and β in human breast cancer and its clinical application. Endocr Relat Cancer 2003;10:193-202.
3. Koehler KF, Helguero LA, Haldosen LA, Warner M, Gustafsson JA. Reflections on the discovery and significance of estrogen receptor β. Endocr Rev 2005;26:465-78.
4. Conneely OM, Jericevic BM, Lydon JP. Progesterone receptors in mammary gland development and tumorigenesis. J Mammary Gland Biol Neoplasia 2003;8:205-14.
5. Balleine RL, Earl MJ, Greenberg ML, Clarke CL. Absence of progesterone receptor associated with secondary breast cancer in postmenopausal women. Br J Cancer 1999;79:1564-71.
6. Gradishar WJ. The future of breast cancer: the role of prognostic factors. Breast Cancer Res Treat 2005;89 Suppl 1:517-26.
7. Weigelt B, Peterse JL, van't Veer LJ. Breast cancer metastasis: markers and models. Nat Rev Cancer 2005;5:591-602.
8. Ross JS, Fletcher JA, Linette GP, et al. The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist 2003;8:307-25.
9. Colozza M, Cardoso F, Sotiriou C, Larsimont D, Piccart MJ. Bringing molecular prognosis and prediction to the clinic. Clin Breast Cancer 2005;6:61-76.
10. Rot A, von Andrian UH. Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells. Annu Rev Immunol 2004;22:891-928.
11. Sallusto F, Mackay CR, Lanzavecchia A. The role of chemokine receptors in primary, effector, and memory immune responses. Annu Rev Immunol 2000;18:593-620.
12. Luboshits G, Shina S, Kaplan O, et al. Elevated expression of the CC chemokine regulated on activation, normal T cell expressed and secreted (RANTES) in advanced breast carcinoma. Cancer Res 1999;59:4681-7.
13. Niwa Y, Akamatsu H, Niwa H, Sumi H, Ozaki Y, Abe A. Correlation of tissue and plasma RANTES levels with disease course in patients with breast or cervical cancer. Clin Cancer Res 2001;7:285-9.
14. Bieche I, Lerebours F, Tozlu S, Espie M, Marty M, Lidereau R. Molecular profiling of inflammatory breast cancer: identification of a poor-prognosis gene expression signature. Clin Cancer Res 2004;10:6789-95
15. Robinson SC, Scott KA, Wilson JL, Thompson RG, Proudfoot AE, Balkwill FR. A chemokine receptor antagonist inhibits experimental breast tumor growth. Cancer Res 2003;63:8360-5.
16. Adler EP, Lemken CA, Katchen NS, Kurt RA. A dual role for tumor-derived chemokine RANTES (CCL5). Immunol Lett 2003;90:187-94.
17. Stormes KA, Lemken CA, Lepre JV, Marinucci MN, Kurt RA. Inhibition of metastasis by inhibition of tumor-derived CCL5. Breast Cancer Res Treat 2005;89:209-12.
18. Azenshtein E, Luboshits G, Shina S, et al. The CC chemokine RANTES in breast carcinoma progression: regulation of expression and potential mechanisms of promalignant activity. Cancer Res 2002;62:1093-102.
19. Azenshtein E, Meshel T, Shina S, Barak N, Keydar I, Ben-Baruch A. The angiogenic factors CXCL8 and VEGF in breast cancer: regulation by an array of pro-malignancy factors. Cancer Lett 2005;217:73-86.
20. Kurt RA, Baher A, Wisner KP, Tackitt S, Urba WJ. Chemokine receptor desensitization in tumor-bearing mice. Cell Immunol 2001;207:81-8.
21. Ben-Baruch A. Breast cancer progression: a "vicious cycle" of pro-malignancy activities is mediated by inflammatory cells, chemokines, and cytokines. 2nd ed., vol. 15. New York: Springer Publishers; 2005. p. 189-217.
22. Ben-Baruch A. Inflammation-associated immune suppression in cancer: the roles played by cytokines, chemokines, and additional mediators. Semin Cancer Biol 2006;16:38-52.
23. Ben-Baruch A. The multifaceted roles of chemokines in malignancy. Cancer and metastasis reviews. In Press.
24. Balkwill F. Cancer and the chemokine network. Nat Rev Cancer 2004;4:540-50.
25. Mantovani A, Allavena P, Sozzani S, Vecchi A, Locati M, Sica A. Chemokines in the recruitment and shaping of the leukocyte infiltrate of tumors. Semin Cancer Biol 2004;14:155-60.
26. Conti I, Rollins BJ. CCL2 (monocyte chemoattractant protein-1) and cancer. Semin Cancer Biol 2004;14:149-54.
27. Bukovsky A, Caudle MR, Cekanova M, et al. Placental expression of estrogen receptor β and its hormone binding variant-comparison with estrogen receptor α and a role for estrogen receptors in asymmetric division and differentiation of estrogen-dependent cells. Reprod Biol Endocrinol 2003;1:36.
28. Bukovsky A, Cekanova M, Caudle MR, et al. Expression and localization of estrogen receptor-α protein in normal and abnormal term placentae and stimulation of trophoblast differentiation by estradiol. Reprod Biol Endocrinol 2003;1:13.
29. Radzikowska E, Langfort R, Giedronowicz D. Estrogen and progesterone receptors in non small cell lung cancer patients. Ann Thorac Cardiovasc Surg 2002;8:69-73.
30. Leake R, Barnes D, Finder S, et al. Immunohistochemical detection of steroid receptors in breast cancer: a working protocol. UK Receptor Group, UK NEQAS, The Scottish Breast Cancer Pathology Group, and The Receptor and Biomarker Study Group of the EORTC. J Clin Pathol 2000;53:634-5.
31. Lebeau A, Deimling D, Kaltz C, et al. Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization. J Clin Oncol 2001;19:354-63.
32. Rodriguez-Burford C, Chhieng DC, et al. p53 and erbB-2 are not associated in matched cases of primary and metastatic ovarian carcinomas. Dis Markers 2003;19:11-7.